Profiling donepezil template into multipotent hybrids with antioxidant properties

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62690094%3A18470%2F18%3A50014446" target="_blank" >RIV/62690094:18470/18:50014446 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/60162694:G44__/18:43889471 RIV/00023752:_____/18:43919338 RIV/00179906:_____/18:10373702

Výsledek na webu

<a href="https://www.ncbi.nlm.nih.gov/pubmed/29529892" target="_blank" >https://www.ncbi.nlm.nih.gov/pubmed/29529892</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/14756366.2018.1443326" target="_blank" >10.1080/14756366.2018.1443326</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Profiling donepezil template into multipotent hybrids with antioxidant properties

Popis výsledku v původním jazyce

Alzheimer&apos;s disease is debilitating neurodegenerative disorder in the elderly. Current therapy relies on administration of acetylcholinesterase inhibitors (AChEIs) -donepezil, rivastigmine, galantamine, and N-methyl-d-aspartate receptor antagonist memantine. However, their therapeutic effect is only short-term and stabilizes cognitive functions for up to 2 years. Given this drawback together with other pathological hallmarks of the disease taken into consideration, novel approaches have recently emerged to better cope with AD onset or its progression. One such strategy implies broadening the biological profile of AChEIs into so-called multi-target directed ligands (MTDLs). In this review article, we made comprehensive literature survey emphasising on donepezil template which was structurally converted into plethora of MTLDs preserving anti-cholinesterase effect and, at the same time, escalating the anti-oxidant potential, which was reported as a crucial role in the pathogenesis of the Alzheimer&apos;s disease. [GRAPHICS] .

Název v anglickém jazyce

Profiling donepezil template into multipotent hybrids with antioxidant properties

Popis výsledku anglicky

Alzheimer&apos;s disease is debilitating neurodegenerative disorder in the elderly. Current therapy relies on administration of acetylcholinesterase inhibitors (AChEIs) -donepezil, rivastigmine, galantamine, and N-methyl-d-aspartate receptor antagonist memantine. However, their therapeutic effect is only short-term and stabilizes cognitive functions for up to 2 years. Given this drawback together with other pathological hallmarks of the disease taken into consideration, novel approaches have recently emerged to better cope with AD onset or its progression. One such strategy implies broadening the biological profile of AChEIs into so-called multi-target directed ligands (MTDLs). In this review article, we made comprehensive literature survey emphasising on donepezil template which was structurally converted into plethora of MTLDs preserving anti-cholinesterase effect and, at the same time, escalating the anti-oxidant potential, which was reported as a crucial role in the pathogenesis of the Alzheimer&apos;s disease. [GRAPHICS] .

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30107 - Medicinal chemistry

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of enzyme inhibition and medicinal chemistry

ISSN

1475-6366

e-ISSN

—

Svazek periodika

33

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

24

Strana od-do

583-606

Kód UT WoS článku

000427559100001

EID výsledku v databázi Scopus

—